Employing deep learning capabilities, the DeepVessel FFR reportedly provides enhanced non-invasive evaluation of coronary arteries through semi-automated analysis of coronary computed tomography angiography (CCTA) imaging.
Keya Medical has launched the DeepVessel FFR, a software device that utilizes deep learning to facilitate fractional flow reserve (FFR) assessment based on coronary computed tomography angiography (CCTA).
Cleared by the Food and Drug Administration (FDA), the DeepVessel FFR provides a three-dimensional coronary artery tree model and estimates of FFR CT value after semi-automated review of CCTA images, according to Keya Medical.
The company said the DeepVessel FFR has demonstrated higher accuracy than other non-invasive tests and suggested the software could help reduce invasive procedures for coronary angiography and stent implantation in the diagnostic workup and subsequent treatment of coronary artery disease.
Joseph Schoepf, M.D., FACR, FAHA, FNASCI, the principal investigator of a recent multicenter trial to evaluate DeepVessel FFR, says the introduction of the modality in the United States dovetails nicely with recent guidelines for the diagnosis of chest pain.
“I am excited to see the implementation of DeepVessel FFR. It comes together with the 2021 ACC/AHA Chest Pain Guidelines’ recognition of the elevated diagnostic role of CCTA and FFR CT for the non-invasive evaluation of patients with stable or acute chest pain,” noted Dr. Schoepf, a professor of Radiology, Medicine, and Pediatrics at the Medical University South Carolina.
(Editor’s note: For related content, see “Can Deep Learning Assessment of X-Rays Improve Triage of Patients with Acute Chest Pain?” and “New CT Protocol May Improve Diagnosis of Acute Chest Pain by 40 Percent.”)